SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001493152-19-012598
Filing Date
2019-08-14
Accepted
2019-08-14 16:46:13
Documents
52
Period of Report
2019-06-30

Document Format Files

Seq Description Document Type Size
1 form10-q.htm 10-Q 619593
2 ex31-1.htm EX-31.1 20528
3 ex32-1.htm EX-32.1 7832
  Complete submission text file 0001493152-19-012598.txt   3179987

Data Files

Seq Description Document Type Size
4 XBRL INSTANCE FILE atrx-20190630.xml EX-101.INS 471880
5 XBRL SCHEMA FILE atrx-20190630.xsd EX-101.SCH 49751
6 XBRL CALCULATION FILE atrx-20190630_cal.xml EX-101.CAL 49255
7 XBRL DEFINITION FILE atrx-20190630_def.xml EX-101.DEF 172379
8 XBRL LABEL FILE atrx-20190630_lab.xml EX-101.LAB 321635
9 XBRL PRESENTATION FILE atrx-20190630_pre.xml EX-101.PRE 229477
Mailing Address 4721 EMPEROR BOULEVARD SUITE 350 DURHAM NC 27703
Business Address 4721 EMPEROR BOULEVARD SUITE 350 DURHAM NC 27703 919-578-5901
Adhera Therapeutics, Inc. (Filer) CIK: 0000737207 (see all company filings)

IRS No.: 112658569 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 000-13789 | Film No.: 191027199
SIC: 2834 Pharmaceutical Preparations